Transvaginal mesh used to repair pelvic organ prolapse (POP) has long been the subject of patient complaints, regulatory investigation, lawsuits and skeptical media reports. The U.S. FDA has been slowly throttling the category since 2011, requiring makers to pull products unless they opted to submit for premarket approval (PMA) by July 2018.